ACADIA Pharmaceuticals Inc. (ACAD) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Catherine E. Owen Adams	Chief Executive Officer & Director	1.78M	1970
Thomas Andrew Garner	Executive Vice President & Chief Commercial Officer	857,023	1976
Jennifer J. Rhodes	Executive Vice President, Chief Legal Officer & Secretary	857,877	1970
Mark C. Schneyer	Executive Vice President & Chief Financial Officer	877,943	1974
Elizabeth Thompson	Executive Vice President and Head of Research & Development	1.04M	1976
Allyson McMillan Youngblood	Senior Vice President of Rare Disease Franchise	0	N/A
Scott Cenci	Senior Vice President, Chief Information & Data Officer	0	N/A
Albert S. Kildani	Senior Vice President of Investor Relations & Corporate Communications	0	N/A
James K. Kihara	Senior Vice President of Finance	0	1981
Rob Ackles	Senior Vice President & Chief People Officer	0	N/A
Konstantina Katcheves	Senior Vice President, Chief Business & Strategy Officer	0	N/A

Name

Title

Pay

Year Born

Catherine E. Owen Adams

Chief Executive Officer & Director

1.78M

1970

Thomas Andrew Garner

Executive Vice President & Chief Commercial Officer

857,023

1976

Jennifer J. Rhodes

Executive Vice President, Chief Legal Officer & Secretary

857,877

1970

Mark C. Schneyer

Executive Vice President & Chief Financial Officer

877,943

1974

Elizabeth Thompson

Executive Vice President and Head of Research & Development

1.04M

1976

Allyson McMillan Youngblood

Senior Vice President of Rare Disease Franchise

N/A

Scott Cenci

Senior Vice President, Chief Information & Data Officer

N/A

Albert S. Kildani

Senior Vice President of Investor Relations & Corporate Communications

N/A

James K. Kihara

Senior Vice President of Finance

1981

Rob Ackles

Senior Vice President & Chief People Officer

N/A

Konstantina Katcheves

Senior Vice President, Chief Business & Strategy Officer

N/A

Description

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.